Masakazu Kakuni

Title: Masakazu Kakuni: Innovator in Hyperuricemia Research

Introduction

Masakazu Kakuni is a notable inventor based in Higashihiroshima, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of animal models for studying hyperuricemia. With a total of 2 patents, his work has implications for understanding and treating conditions related to uric acid metabolism.

Latest Patents

Kakuni's latest patents include a mouse model of hyperuricemia, which provides a non-human animal that is highly practical as a hyperuricemia model. This model is characterized by a chimeric non-human animal carrying human hepatocytes. The chimeric non-human animal has an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted. Additionally, he has developed a method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system, which is provided with a drug-metabolizing system driven by human hepatocytes. This method involves transplanting human hepatocytes into a non-human animal that is immunodeficient, has liver damage, and lacks the functions of an endogenous Cyp3a gene.

Career Highlights

Throughout his career, Kakuni has worked with various esteemed institutions, including Phoenixbio Co., Ltd. and Tottori University. His research has focused on creating innovative models that enhance the understanding of drug metabolism and disease mechanisms.

Collaborations

Kakuni has collaborated with notable colleagues such as Chise Mukaidani and Yumiko Iwasaki, contributing to the advancement of research in his field.

Conclusion

Masakazu Kakuni's work in developing animal models for hyperuricemia represents a significant advancement in biomedical research. His innovative patents and collaborations highlight his commitment to improving our understanding of complex metabolic conditions.